Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in treatment-experienced patients. In the DUET 1 and 2 trials, 1203 highly treatment-experienced patients were randomized to etravirine or placebo, in combination with darunavir/ritonavir and optimized b...
Saved in:
| Main Authors: | Mark Nelson, Andrew Hill, Yvon van Delft, Christiane Moecklinghoff |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2014/636584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients
by: Gloria Huerta García, et al.
Published: (2016-06-01) -
Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network
by: Kelly Gebo, et al.
Published: (2013-01-01) -
Study of the physicochemical properties of the etravirine substance
by: S. A. Zolotov, et al.
Published: (2021-11-01) -
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
by: Thomas Kakuda, et al.
Published: (2012-01-01) -
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
by: Catherine Orrell, et al.
Published: (2015-01-01)